The Special Drug Use-results Survey (All-Case Surveillance) of Ofev Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2017 Planned End Date changed from 30 Aug 2018 to 31 Jan 2020.
- 22 Aug 2017 Planned primary completion date changed from 30 Aug 2018 to 31 Jan 2020.